KemPharm Inc. (NASDAQ: KMPH) registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering. The company expects to price its 3 million shares around Thursday’s closing price of $18.88, with an overallotment option for an additional 450,000 shares. This would value the entire offering at roughly $65.14 million.
The underwriters for the offering are Cowen, RBC Capital Markets, Canaccord Genuity and Oppenheimer.
This is a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that it believes will be improved versions of widely prescribed, approved drugs. KemPharm employs its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The company believes its prodrugs will be eligible for composition-of-matter patent protection.
For a little background: A prodrug is a precursor chemical compound of a drug that is inactive or less than fully active, which is then converted in the body to its active form through a normal metabolic process.
At the end of November, the patent portfolio consisted of 47 granted patents and 75 pending patent applications worldwide, including a granted U.S. composition-of-matter patent covering KP201, a granted U.S. patent covering KP201-related compositions-of-matter, and granted U.S. composition-of-matter patents covering the prodrugs underlying two of its other product candidates.
The most advanced product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, combined with acetaminophen (APAP). The company is developing KP201/APAP as an immediate release product candidate for the short-term management of acute pain. KemPharm submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in December 2015, and the company believes it will receive priority review like other abuse-deterrent opioids.
Shares of KemPharm closed Friday up 2.3% at $19.31, with a consensus analyst price target of $34.75 and a 52-week trading range of $10.90 to $26.15.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
